Obermatt

Flags

Earnings warning

Orion

HEX:ORNBV · FI0009014377
PharmaceuticalsLarge

360

80
EV / EBIT54
Price / Owner Earnings65
Owner Earnings Yield68
Dividend Yield73
Price/Sales40
EV / Gross Profit32
Price/Book14
Return on Capital99
Cash Return on Capital96
Return on Equity97
EBIT Margin92
Gross Profitability90
Cash Conversion11
Accruals12
Owner Earnings Margin83
Sales growth66
Profit Growth65
Long-Term EPS Growth67
Owner Earnings Growth75
Reinvestment19
Price momentum50
Debt load51
Refinancing75
Debt Payback32
Liquidity92
Analyst ratings54
Opinion Changes50
Price Target Upside40
Market mood59
Value Creation20/20strong value creator
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Orion generates returns well above its cost of capital, the foundation of durable shareholder value.

Profile

CountryFinland
IndustryPharmaceuticals
SizeLarge
TypePublic Company
ExchangeHLSE
Employees2,069
ISINFI0009014377
Last UpdateApr 2, 2026
Themes
RheumatologyPain ManagementCardiovascularPulmonologyRespiratoryNeurologyWomen's HealthOncologyCentral Nervous SystemChronic DiseasesPharmaceutical

Description

Orion Oyj is a Finnish pharmaceutical company committed to developing and providing innovative products in the healthcare sector, primarily focusing on pharmaceuticals and active pharmaceutical ingredients (APIs). The company operates globally and…

Analysis

Middle-of-the-road

Orion Oyj sits in the middle of our grid: average quality, average price, no obvious signal in either direction. Worth noting: the cash the business generates has lagged behind what the income statement shows.

On valuation, the picture is fair. The owner-earnings multiple stands at 19.0×; owner earnings: the cash an owner could take out each year. The implied growth embedded in that price is around 6% a year, against analyst forecasts of 14%. The price, in other words, assumes less than the experts do.

Growth is moderate; the safety picture is sturdy. The company scores 20/20 on our value-creation score: strong value creator.

Flags to be aware of: Reported profits have run ahead of actual cash for several periods. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250
78
2023202420252026

All-time high

84

Jan 2025

All-time low

6

Aug 2023

Average rank

54

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
40
15
26
42
Price/Earnings
34
27
27
39
Price/Book
14
8
8
22
Dividend Yield
73
80
92
96
Value (overall)
35
27
34
35

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Orion with its peers
AstraZeneca
LSE:AZN
67
CountryUK
IndustryPharmaceuticals
SizeXX-Large
Full Stock Analysis →
GSK
LSE:GSK
72
CountryUK
IndustryPharmaceuticals
SizeXX-Large
Full Stock Analysis →
Evotec
GER:EVT
17
CountryGermany
IndustryLife Sciences Tools & Services
SizeMedium
Full Stock Analysis →
Sandoz
SWX:SDZ
18
CountrySwitzerland
IndustryPharmaceuticals
SizeX-Large
Full Stock Analysis →
GlaxoSmithKline Pharmaceuticals
NSI:GLAXO
53
CountryUK
IndustryPharmaceuticals
SizeMedium
Full Stock Analysis →
Bayer
GER:BAYN
15
CountryGermany
IndustryPharmaceuticals
SizeXX-Large
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →